SCHEMBL6286272

SCHEMBL6286272

Nc1ccccc1C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.36
ALOX15 P16050 2/20 0.36
CYP3A4 P08684 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
ALDH1A1 P00352 3/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
LMNA P02545 2/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
NFKB1 P19838 1/20 0.32
POLB P06746 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
MAPT P10636 3/20 0.31
KDM4E B2RXH2 2/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2255922 1.00 SMN1; SMN2 (0.36) SMN1; SMN2ALOX15CYP3A4CASP1CASP7
SCHEMBL10660181 0.98 SMN1; SMN2 (0.38) SMN1; SMN2ALOX15CYP3A4CASP1CASP7
SCHEMBL9297116 0.94 CYP3A4 (0.41) SMN1; SMN2ALOX15CYP3A4CASP1CASP7
SCHEMBL15053474 0.94 CYP3A4 (0.41) SMN1; SMN2ALOX15CYP3A4CASP1CASP7
SCHEMBL6279751 0.91 SMN1; SMN2 (0.39) SMN1; SMN2ALOX15CYP3A4CASP1CASP7
SCHEMBL9296553 0.91 CYP3A4 (0.43) SMN1; SMN2ALOX15CYP3A4CASP1CASP7
SCHEMBL9483114 0.87 CYP3A4 (0.43) SMN1; SMN2ALOX15CYP3A4CASP1CASP7
SCHEMBL6004102 0.85 CYP3A4 (0.41) SMN1; SMN2ALOX15CYP3A4CASP1CASP7
SCHEMBL28730692 0.84 LMNA (0.39) ALDH1A1L3MBTL1LMNACA1CA2
SCHEMBL3871150 0.82 SMN1; SMN2 (0.43) SMN1; SMN2ALOX15CYP3A4CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919291-B2 Fluorinated zwitterionic cocatalyst activators for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2005-07-19 US disclosed
US-20040110631-A1 Fluorinated zwitterionic cocatalyst activators for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2004-06-10 US disclosed
EP-1349653-A2 FLUORINATED ZWITTERIONIC COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION ExxonMobil Chemical Patents Inc. (US) 2003-10-08 EP disclosed
WO-2002036639-A2 FLUORINATED ZWITTERIONIC COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2002-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110631-A1 Fluorinated zwitterionic cocatalyst activators for olefin polymerization FZD7, FOS, COG4 SMN1; SMN2 4185/4885ALOX15 386/4885CYP3A4 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.